- Companies
- Mammoth Biosciences
Mammoth Biosciences Valuation, Funding & Investors
Mammoth Biosciences is valued at $1B as of September 2021.
Last Mammoth Biosciences valuation
$1B
Series D · Sep 2021
Last Mammoth Biosciences funding round
$95M
Strategic investment · Apr 2024
Cumulative funding Mammoth Biosciences raised
$360M
across 7 funding rounds
Key investors in Mammoth Biosciences
NFX
Mayfield Fund
Decheng Capital
Plum Alley
Tachyon Ventures
8VC
About Mammoth Biosciences
Mammoth Biosciences is a biotechnology company, co-founded by CRISPR pioneer Jennifer Doudna, that develops CRISPR-based tools for diagnostics and gene-editing therapeutics. Its platform is built around compact Cas proteins such as Cas14 and Casφ, which the company applies to in vivo gene editing for genetic and infectious diseases as well as decentralized disease detection. Mammoth has partnered with organizations including Regeneron, GSK, and the NIH, and has received government funding to develop COVID-19 testing technology.
Founded
2017
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Licensing
Valuation
$1B (Sep 2021)
Mammoth Biosciences Valuation
Mammoth Biosciences is currently valued at $1B, based on its Series D in September 2021.
The $150M round was led by Redmile Group, with participation from Greenspring Associates, Bradley Horowitz, Decheng Capital, Jason Haider, Foresite Capital and 6 other investors.
Mammoth Biosciences valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Sep 2021 | Series D | $1B |
Mammoth Biosciences Funding History
Mammoth Biosciences has raised a total of $360M across 7 funding rounds.
Mammoth Biosciences' first fundraising round was a $100K pre-seed round in May 2017. The most recent completed round was a $95M strategic investment round in April 2024.
Mammoth Biosciences funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Apr 2024 | Strategic investment | Regeneron (lead) | $95M | - | Mammoth Biosciences, a CRISPR drug developer, announced a collaboration with Regeneron Pharmaceuticals on April 25, 2024, to research, develop, and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The deal combines Mammoth's ultracompact nucleases and gene editing systems with Regeneron's adeno-associated viral vector delivery technology enhanced by antibody-based targeting. Under the five-and-a-half-year agreement, which Regeneron can extend by two years, Mammoth receives $100 million upfront, including $95 million in equity investment and $5 million in cash, plus up to $370 million per target in milestones and royalties from single to mid-teens on net sales. Regeneron leads target selection jointly with Mammoth initially, then handles development and commercialization, gaining broad access to Mammoth's editing technologies except for excluded targets. Mammoth has the option to co-fund and share profits on most programs instead of milestones and royalties. The partnership advances Mammoth's mission to transform patient lives through CRISPR technologies, building on its proprietary platform and intellectual property portfolio. Regeneron, expanding in genetic medicines, leverages this deal alongside collaborations like Intellia Therapeutics and acquisitions in gene and cell therapy. |
| Sep 2021 | Series D | Redmile Group (lead); Greenspring Associates; Bradley Horowitz; Decheng Capital; Jason Haider; Foresite Capital; Sixth Street; Tachyon Ventures; NFX; Plum Alley; Senator Investment Group; Mayfield Fund | $150M | $1B | Mammoth Biosciences, co-founded by CRISPR pioneer Jennifer Doudna, develops next-generation CRISPR products for diagnostics and therapeutics, leveraging novel proteins like ultra-small Cas14 and Casφ for in vivo gene editing and sensitive disease detection. The company announced a $150 million Series D round on September 9, 2021, led by Redmile Group, with participation from Foresite Capital, Senator Investment Group, Sixth Street, Greenspring Associates, Mayfield, Decheng Capital, NFX, and Plum Alley, achieving unicorn status with over $1 billion valuation. This followed an unannounced $45 million Series C in late 2020, also led by Redmile and Foresite with Amazon participation, bringing total funding to $195 million from these two rounds and prior raises. The Series D funding enables expansion of Mammoth's CRISPR platform, particularly for in vivo therapeutics targeting genetic cures and decentralized on-demand diagnostics partnered with NIH RADx, DARPA, and GSK. At the time, the company had grown to over 110 employees from 30 since its Series B in January 2020, with preclinical progress in therapeutics using smaller Cas14 and Casφ proteins compared to Cas9. Mammoth distinguishes itself in the competitive CRISPR landscape by focusing on both diagnostics and therapeutics, resisting pressure to specialize, with potential for pharma partnerships to advance clinical development. Investors view the unicorn valuation as validation of its dual approach and technical promise in programmable molecular medicine for infectious diseases and genetic therapies. |
| Nov 2020 | Series C | Foresite Capital (lead); NFX (lead); Redmile Group (lead); Amazon; Decheng Capital; Sixth Street; Mayfield Fund | $45M | - | Mammoth Biosciences develops CRISPR-based platforms for diagnostics, gene-editing, and therapeutics, co-founded by Nobel laureate Jennifer Doudna and others. The company focuses on novel Cas systems like Cas14 for disease detection, in vivo therapies, and partnerships with biotechs. In January 2020, it raised an oversubscribed $45M Series B led by Decheng Capital with Mayfield, NFX, Verily, and Brook Byers, bringing total funding over $70M to advance diagnostics and expand into therapeutics. A $45M Series C followed in November 2020 led by Foresite Capital, NFX, and Redmile Group to scale diagnostic pipelines and enter new therapeutic markets; later Series D in September 2021 valued the firm at $1B. Mammoth secured government funding like $23.1M in July 2020 for COVID-19 testing and leverages its extensive CRISPR protein toolbox for applications in healthcare, agriculture, and biodefense. |
| Jan 2020 | Series B | Decheng Capital (lead); Verily; aMoon Fund; Pacific 8 Ventures; Tachyon Ventures; NFX; Brook Byers; Plum Alley; Mayfield Fund | $45M | - | Mammoth Biosciences, co-founded by CRISPR pioneer Jennifer Doudna and principals Trevor Martin, Janice Chen, and Lucas Harrington, develops a CRISPR-based platform for disease detection, gene-editing, and therapeutics applications. The company announced an oversubscribed $45 million Series B funding round on January 30, 2020, led by Decheng Capital, with participation from Mayfield, NFX, Verily, Brook Byers, Plum Alley, Pacific 8 Ventures, aMoon Fund, and others. The funds were intended to advance CRISPR diagnostics, expand into next-generation CRISPR products including gene-editing and therapeutics, and explore partnerships with biotech and pharmaceutical companies. Mammoth leverages an extensive portfolio of novel Cas systems, including exclusive licensing to Cas12, Cas13, and Cas14, positioning it as a leader in CRISPR-based disease detection with applications in life science research, healthcare, agriculture, and biodefense. The Series B focused particularly on developing the Cas14 system. Based in San Francisco (later Brisbane, CA), the company had previously raised $23 million in a Series A in July 2018 led by Mayfield Fund to scale R&D and commercialize CRISPR diagnostics. Subsequent rounds included a $45 million Series C in late November 2020 led by Redmile Group and Foresite Capital with NFX participation, and a $195 million Series D in September 2021 led by Redmile Group, achieving unicorn status with over $1 billion valuation. |
| Jul 2018 | Series A | Mayfield Fund (lead); SV Angel; Tectonic Capital; 8VC; Tim Cook; Tachyon Ventures; NFX; DHVC; Plum Alley; Jeff Huber | $23M | - | Mammoth Biosciences, a biotechnology company co-founded by CRISPR pioneer Jennifer Doudna, emerged from stealth in 2018 with a focus on leveraging diverse CRISPR systems for disease detection and therapeutics. The company raised $23 million in a Series A round on July 31, 2018, led by Mayfield Fund, with participation from 8VC, NFX, and others including DHVC, Jeff Huber, Plum Alley, SV Angel, Tachyon Ventures, Tectonic Capital, and Tim Cook. This followed a small $120,000 pre-seed from NFX. The funding aimed to support key hires, expand the IP portfolio, develop a CRISPR-based platform for biomarker detection via nucleic acid assays without specialized devices, and pursue partnerships in pharmaceuticals, agriculture, and affordable point-of-care testing in developing regions. Led by CEO Trevor Martin and CTO Ashley Tehranchi (both Stanford PhDs), along with Berkeley PhDs Lucas Harrington and Janice Chen, Mammoth positioned its technology as a transformative search engine for diagnostics, reducing costs and enabling broad applications. The round announcement highlighted additions to its scientific advisory board, including protein engineering expert Dave Savage and infectious disease specialist Charles Chui, with Doudna serving as chair. Post-2018, Mammoth continued scaling, achieving unicorn status by 2021 with a $195 million raise at over $1 billion valuation and total funding reaching approximately $264.5 million across rounds. The company operates from Brisbane, California, competing in the CRISPR diagnostics space with potential to disrupt healthcare through low-cost, device-free testing. |
| Nov 2017 | Seed | NFX (lead); K50 Ventures | $1M | - | - |
| May 2017 | Pre-seed | NFX (lead); 8VC; AME Cloud Ventures; Wireframe Ventures; Mayfield Fund | $100K | - | - |
Who has invested in Mammoth Biosciences?
27 investors have backed Mammoth Biosciences across its funding rounds, including NFX, Mayfield Fund, Decheng Capital, Plum Alley, Tachyon Ventures and 8VC.
Lead investors include Regeneron, Redmile Group, Foresite Capital, NFX, Decheng Capital and 1 other investor.
Mammoth Biosciences Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 6 | Lead | May 2017 | ||
| 5 | Lead | May 2017 | ||
| 3 | Lead | Jan 2020 | ||
| 3 | Participant | Jul 2018 | ||
| 3 | Participant | Jul 2018 | ||
| 2 | Lead | Nov 2020 | ||
| 2 | Participant | May 2017 | ||
| 2 | Lead | Nov 2020 | ||
| 2 | Participant | Nov 2020 | ||
| 1 | Participant | Jan 2020 | ||
| 1 | Participant | Sep 2021 | ||
| 1 | Participant | Jul 2018 | ||
| 1 | Participant | Jul 2018 | ||
This data is available for Pro users. Sign up to see all 27 Mammoth Biosciences investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialMammoth Biosciences Competitors
Mammoth Biosciences competitors include listed companies like Personalis, Korro Bio, 10x Genomics and Illumina, and private ones like Inscripta and Character Biosciences.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $70M | ($78M) | $1.7B | 20.1x | ||
| Private | - | - | $565M | - | ||
| Private | - | - | $356M | - | ||
| Publicly listed | $6M | ($112M) | $174M | 48.9x | ||
| Publicly listed | $643M | ($16M) | $10B | 15.2x | ||
| Publicly listed | $4.3B | $1.4B | $37B | 8.4x |
Mammoth Biosciences Public Comps
Mammoth Biosciences is still privately-owned, but its public comps include SEEGENE, Bide Pharmatech Co, Castle Biosciences, Novogene, Eckert & Ziegler, CryoPort, OPKO Health, VCANBIO, SOPHiA Genetics and Genfit.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $345M | $85M | 2.3x | 2.1x | 9.2x | 7.7x | |||
| $197M | $33M | 3.8x | 3.5x | 22.7x | - | |||
| $344M | ($429K) | 2.6x | 2.5x | (2082.6x) | 44.9x | |||
| $329M | $50M | 1.9x | 1.9x | 12.5x | 13.5x | |||
| $359M | $105M | 2.2x | 2.2x | 7.5x | 7.4x | |||
| $176M | ($2M) | 4.2x | 3.9x | (349.1x) | (974.7x) | |||
| $607M | ($56M) | 2.2x | 2.3x | (23.3x) | (11.2x) | |||
| $217M | $44M | 4.6x | 4.3x | 22.8x | 25.1x | |||
This data is available for Pro users. Sign up to see all Mammoth Biosciences competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Mammoth Biosciences
| When was Mammoth Biosciences founded? | Mammoth Biosciences was founded in 2017. |
| Where is Mammoth Biosciences headquartered? | Mammoth Biosciences is headquartered in United States. |
| Is Mammoth Biosciences publicly listed? | No, Mammoth Biosciences is a private, VC-backed company. |
| What is Mammoth Biosciences' valuation? | Mammoth Biosciences was last valued at $1B in its Series D in September 2021. |
| How much funding has Mammoth Biosciences raised? | Mammoth Biosciences has raised $360M across 7 funding rounds. |
| What was Mammoth Biosciences' last funding round? | Mammoth Biosciences' last funding round was a $95M strategic investment round in April 2024, led by Regeneron. |
| Who are Mammoth Biosciences' investors? | Mammoth Biosciences' investors include NFX, Mayfield Fund, Decheng Capital, Tachyon Ventures, Plum Alley, Redmile Group, 8VC, Foresite Capital, Sixth Street, Verily and 17 others. |
| Which companies are comparable to Mammoth Biosciences? | Companies comparable to Mammoth Biosciences include Personalis, Inscripta, Character Biosciences, Korro Bio, 10x Genomics and Illumina. |
See companies similar to Mammoth Biosciences
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




